Document Detail

Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
MedLine Citation:
PMID:  17244215     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To compare the ocular hypotensive efficacy and safety of topical bimatoprost and timolol-dorzolamide combination in patients with primary open-angle glaucoma (POAG) or ocular hypertension during 6 months of treatment. METHODS: A sample of 65 patients with a diagnosis of POAG or ocular hypertension were randomized to receive either bimatoprost 0.03% once daily or timolol-dorzolamide combination twice daily. Study visits occurred at baseline and after 2 weeks and 1, 3 and 6 months of therapy. Intraocular pressure (IOP) measurements were performed at 12.00 hours at all study visits and also at 08.00 hours and 16.00 hours at baseline and 6-month visits. At each visit, local and systemic side-effects that occurred during the treatment period were recorded. Student's t-test was used to compare the differences between IOP values. RESULTS: Differences in IOP between the bimatoprost and timolol-dorzolamide groups were statistically insignificant at all study visits (p > 0.05). In the bimatoprost-treated group, the IOP reduction was 6.2 +/- 1.8 mmHg, whereas it was 6.5 +/- 2.3 mmHg in the timolol-dorzolamide group after 6 months of treatment. The difference was not statistically significant (p = 0.48). CONCLUSIONS: The IOP-lowering efficacies of bimatoprost and timolol-dorzolamide combination were similar over a 6-month follow-up. Both bimatoprost and the timolol-dorzolamide combination were well tolerated. Bimatoprost can be used as a longterm monotherapy agent in the treatment of POAG and ocular hypertension.
Faruk Ozturk; Sitki Samet Ermis; Umit Ubeyt Inan
Related Documents :
6133515 - Timolol maleate: side effects on healthy nonglaucomatous volunteers.
1420055 - Ocular circulatory changes following scleral buckling procedures.
11310895 - Intraocular pressure and tear production in captive eland and fallow deer.
3946535 - Effect of adding betaxolol to dipivefrin therapy.
21223545 - Global response of plasmodium falciparum to hyperoxia: a combined transcriptomic and pr...
419425 - Multiple transverse taeniamyotomy for diverticular disease.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Acta ophthalmologica Scandinavica     Volume:  85     ISSN:  1395-3907     ISO Abbreviation:  Acta Ophthalmol Scand     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-01-24     Completed Date:  2007-03-15     Revised Date:  2008-03-17    
Medline Journal Info:
Nlm Unique ID:  9507578     Medline TA:  Acta Ophthalmol Scand     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  80-3     Citation Subset:  IM    
Department of Ophthalmology, School of Medicine, University of Afyon Kocatepe, Afyon, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amides / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Cloprostenol / adverse effects,  analogs & derivatives*,  therapeutic use
Drug Therapy, Combination
Glaucoma, Open-Angle / drug therapy*
Intraocular Pressure / drug effects*
Lipids / adverse effects,  therapeutic use*
Middle Aged
Ocular Hypertension / drug therapy
Prospective Studies
Single-Blind Method
Sulfonamides / adverse effects,  therapeutic use*
Thiophenes / adverse effects,  therapeutic use*
Timolol / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Amides; 0/Antihypertensive Agents; 0/Lipids; 0/Sulfonamides; 0/Thiophenes; 0/bimatoprost; 130693-82-2/dorzolamide; 26839-75-8/Timolol; 40665-92-7/Cloprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Frequency-doubling technology: searching for the optimum diagnostic criteria for glaucoma.
Next Document:  Improved accuracy of intraocular lens power calculation with the Zeiss IOLMaster.